Abstract
An increased cardiovascular morbidity and mortality have been linked with overt and subclinical hyperthyroidism. These findings might be the consequence of the increased risk of atrial fibrillation, embolic events, heart failure, and coronary disease observed in the presence of thyroid hormone excess. A specific autoimmune cardiovascular involvement has been reported in patients with Graves’ disease. Pulmonary hypertension, cardiac valve disease, and dilated cardiomyopathy represent important risk factors, which may play an important role in determining the poor cardiovascular outcome reported in autoimmune hyperthyroidism. The correction of overt and subclinical hyperthyroidism should be the first step in improving the prognosis of hyperthyroid patients with cardiovascular complications.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cooper DS. Hyperthyroidism. Lancet. 2003;362:459–68.
Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358:2594–605.
Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.
Jenkins RC, Weetman AP. Disease associations with autoimmune thyroid disease. Thyroid. 2002;12(11):977–88.
Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229:415–20.
Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86:930–4.
Brand OJ, Gough SCL. Genetics of thyroid autoimmunity and the role of the TSHR. Mol Cell Endocrinol. 2010;322:135–43.
Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease. Immunol Res. 2012;54:191–203.
Madden PA, Pedersen NL, Kaprio J, Koskenvuo MJ, Martin NG. The epidemiology and genetics of smoking initiation and persistence: cross cultural comparisons of twin study results. Twin Res. 2004;7:82–97.
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69–75.
Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431–43.
Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab. 1988;67:656–62.
Díez JJ. Hyperthyroidism in patients older than 55 years: an analysis of the etiology and management. Gerontology. 2003;49(5):316–23.
Völzke H, Schwahn C, Wallaschofski H, Dörr M. The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab. 2007;7(92):2421–9.
Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–7.
Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148:832–45.
Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008;159:329–41.
Yang LB, Jiang DQ, Qi WB, et al. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol. 2012;167:75–84.
Collet TH, Gussekloo J, Bauer DC et al for the Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799–809.
Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31–50.
Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab. 2002;87:968–74.
Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid. 2002;12:473–81.
Kahaly GJ, Nieswandt J, Wagner S, Schlegel J, Mohr-Kahaly S, Hommel G. Ineffective cardiorespiratory function in hyperthyroidism. J Clin Endocrinol Metab. 1998;83:4075–8.
Engel AG. Neuromuscular manifestations of Graves’ disease. Mayo Clin Proc. 1972;47(12):919–25.
Gold HK, Spann Jr JF, Braunwald E. Effects of alterations in the thyroid state on the intrinsic contractile properties of isolated rat skeletal muscle. J Clin Invest. 1970;49:849–54.
Lovejoy JC, Smith SR, Bray GA, et al. A paradigm of experimentally induced mild hyperthyroidism: effects on nitrogen balance, body composition, and energy expenditure in healthy young men. J Clin Endocrinol Metab. 1997;82:765–70.
Fukui H, Taniguchi S, Ueta Y, et al. Enhanced activity of the purine nucleotide cycle of the exercising muscle in patients with hyperthyroidism. J Clin Endocrinol Metab. 2001;86:2205–10.
Kaminski HJ, Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic corticosteroid myopathy). In: Engel AG, Franzini-Armstrong C, editors. Myology. 2nd ed. New York, NY: McGraw-Hill; 1994. p. 1726–53.
Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750–5.
Olson BR, Klein I, Benner R, Burdett R, Trzepacz P, Levey GS. Hyperthyroid myopathy and the response to treatment. Thyroid. 1991;1:137–1341.
Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med. 1984;77:733–5.
Marinó M, Ricciardi R, Pinchera A, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab. 1997;82:438–43.
Kiessling WR, Finke R, Kotulla P, Schleusener H. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol (Copenh). 1982;101:41–6.
Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80:99–105.
Ghose R, Quail G, King R, Moloney P. Hypokalemic paralysis in remote aboriginal communities. Aust Fam Physician. 1996;25:1172–3.
Lin SH, Huang CL. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol. 2012;23:985–8.
Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation flutter: a population-based study. Arch Intern Med. 2004;164:1675–8.
Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006;64:323–9.
Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke. 2010;41:961–6.
Lin HC, Yang LY, Kang JH. Increased risk of pulmonary embolism among patients with hyperthyroidism: a 5-year follow-up study. J Thromb Haemost. 2010;8:2176–81.
Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005;36:2302–10.
Biondi B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol. 2012;167:609–18.
De Groot WJ, Leonard JJ. Hyperthyroidism as a high cardiac output state. Am Heart J. 1970;79:265–75.
Yu YH, Bilezikian JP. Tachycardia-induced cardiomyopathy secondary to thyrotoxicosis: a young man with previously unrecognized Graves’ disease. Thyroid. 2000;10:923–7.
Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol. 1990;16:739–44.
Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart. 2007;93:483–7.
Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010;6:473–7.
Yue WS, Chong BH, Zhang XH, et al. Hyperthyroidism-induced left ventricular diastolic dysfunction: implication in hyperthyroidism-related heart failure. Clin Endocrinol (Oxf). 2011;74:636–43.
Cavros NG, Old WD, Castro FD, Estep HL. Case report: reversible mitral regurgitation and congestive heart failure complicating thyrotoxicosis. Am J Med Sci. 1996;311:142–4.
Kage K, Kira Y, Sekine I, et al. High incidence of mitral and tricuspid regurgitation in patients with Graves’ disease detected by two-dimensional color Doppler echocardiography. Intern Med. 1993;32:374–6.
Kahaly G. Graves’ disease and mitral valve prolapse. JAMA. 1987;257:252.
Kahaly GJ, Mohr-Kahaly S, Beyer J, Meyer J. Prevalence of myxomatous mitral valve prolapse in patients with lymphocytic thyroiditis. Am J Cardiol. 1995;76:1309–10.
Khoo DH, Parma J, Rajasoorya C, Ho SC, Vassart G. A germline mutation of the thyrotropin receptor gene associated with thyrotoxicosis and mitral valve prolapse in a Chinese family. J Clin Endocrinol Metab. 1999;84:1459–62.
Siu CW, Zhang XH, Yung C, Kung AW, Lau CP, Tse HF. Hemodynamic amic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab. 2007;2:1736–42.
Li JH, Safford RE, Aduen JF, Heckman MG, Crook JE, Burger CD. Pulmonary hypertension and thyroid disease. Chest. 2007;132:793–7.
Marvisi M, Brianti M, Marani G, Del Borello R, Bortesi ML, Guariglia A. Hyperthyroidism and pulmonary hypertension. Respir Med. 2002;96:215–20.
Armigliato M, Paolini R, Aggio S, et al. Hyperthyroidism as a cause of pulmonary arterial hypertension: a prospective study. Angiology. 2006;57:600–6.
Nakchbandi IA, Wirth JA, Inzucchi SE. Pulmonary hypertension caused by Graves’ thyrotoxicosis. Chest. 1999;116:1483–5.
Merce J. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med. 2005;118:126–31.
Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest. 2002;122:1668–73.
Ma RC, Cheng AY, So WY, Hui DS, Tong PC, Chow CC. Thyrotoxicosis and pulmonary hypertension. Am J Med. 2005;118:927–8.
Badesch DB, Wynne KM, Bonvallet S, Voelkel NF, Ridgway C, Groves BM. Hypothyroidism and primary pulmonary hypertension: an autoimmune pathogenetic link. Ann Intern Med. 1993;119:44–6.
Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev. 2004;12:299–305.
Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med. 2007;22:148–50.
Berlin T, Lubina A, Levy Y, Shoenfeld Y. Graves’ disease presenting as right heart failure. Isr Med Assoc J. 2008;8:217–8.
Cohen J, Shattner A. Right heart failure and hyperthyroidism: a neglected presentation. Am J Med. 2003;11:576–7.
Shirani J, Barron MM, Pierre-Louis ML, Roberts WC. Congestive heart failure, dilated cardiac ventricles, and sudden death in hyperthyroidism. Am J Cardiol. 1993;72:365–8.
Fatourechi V, Edwards WD. Graves’ disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients. Thyroid. 2000;10:601–5.
Boccaladro C, Boccalandro F, Orlander P, Wei CF. Severe reversible dilated cardiomyopathy and hyperthyroidism: case report and review of the literature. Endocr Pract. 2003;9:140–6.
Londhey VA, Kamble US, Limaye CS, Pednekar SJ, Kini SH, Borges NE. Irreversible dilated cardiomyopathy due to thyrotoxicosis. J Assoc Physicians India. 2006;54:575–6.
Ebisawa K, Ikeda U, Murata M, et al. Irreversible cardiomyopathy due to thyrotoxicosis. Cardiology. 1994;84:274–7.
Al-Ghamdi AS, Aljohani N. Graves’ thyrotoxicosis-induced reversible cardiomyopathy: a case report. Clin Med Insights Case Rep. 2013;27:47–50.
Eliades M, El-Maouche D, Choudhary C, Zinsmeister B, Burman KD. Takotsubo cardiomyopathy associated with thyrotoxicosis: a case report and review of the literature. Thyroid. 2014;24:383–9.
Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000;35:701–5.
Gleicher N, Elkayam U. Peripartum cardiomyopathy, an autoimmune manifestation of allograft rejection? Autoimmun Rev. 2009;8:384–7.
Valko PC, Carty DL. Peripartum cardiac failure in a woman with Graves’ disease. Am J Emerg Med. 1992;10:46–9.
Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010;55:654–9.
Nabriski D, Ellis M, Ness-Abramof R, Shapiro M, Shenkman L. Autoimmune thyroid disease and antiphospholipid antibodies. Am J Hematol. 2000;64:73–5.
Khochtali I, Hamza N, Gassab E, et al. Graves’ disease associated with cerebrovascular disease and antiphospholipid antibody syndrome. Int J Endocrinol. 2010;2010:1–3.
Mayaudon H, Crozes P, Riveline JP, Boyer B, Simon P, Bauduceau B. Antiphospholipid antibodies in Basedow disease. Presse Med. 1994;23:1496.
Mouelhi L, Chaieb M, Debbeche R, et al. Association Budd Chiari syndrome, antiphospholipid syndrome and graves’ disease. Tunis Med. 2009;87:164–6.
Hofbauer LC, Spitzweg C, Heufelder AE. Graves’ disease associated with the primary antiphospholipid syndrome. J Rheumatol. 1996;23:1435–7.
Jain A. Antiphospholipid antibody syndrome associated with graves’ disease presenting as inferior vena cava thrombosis with bilateral lower limb DVT. Clin Med Insights Case Rep. 2014;16:37–9.
Völzke H, Schwahn C, Wallaschofski H, Dörr M. Review: the association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab. 2007;92:2421–9.
Brand F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–7.
Brandt F, Thvilum M, Almind D, et al. Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013;23:408–13.
Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedüs L. Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab. 2012;97:4123–9.
Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013;20(8):e66711.
Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab. 2013;98:1869–82.
Ryödi E, Salmi J, Jaatinen P, et al. Cardiovascular morbidity and mortality in surgically treated hyperthyroidism—a nation-wide cohort study with a long-term follow-up. Clin Endocrinol (oXF). 2014;80:743–50.
Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–6.
Nyrienda MJ, Clark DN, Finlaysa AR, et al. Thyroid disease and increased cardiovascular risk. Thyroid. 2005;15:718–24.
Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2003;85:4701–5.
Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137:904–14.
Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131.
Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–54.
Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.
Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033–41.
Gencer B, Collet TH, Virgini v, et al. Thyroid Studies Collaboration. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from six prospective cohorts. Circulation. 2012;126:1040–9.
Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.
Osman F, Franklyn J, Holder RL, Sheppard MC, Gammage MD. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case–control study. J Am Coll Cardiol. 2007;49:71–81.
Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol. 2012;167:295–9.
Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98:3671–7.
Bahn RS. Is radioiodine more likely than antithyroid drugs to worsen ophthalmopathy in patients with Graves disease? Nat Clin Pract Endocrinol Metab. 2008;4:594–5.
Nakazawa K, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982;72:903–6.
Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12:489–93.
Anderson JL, Halperin JL, Albert NM. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:1935–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Biondi, B. (2015). Impact of Hyperthyroidism on the Cardiovascular and Musculoskeletal Systems and Management of Patients with Subclinical Graves’ Disease. In: Bahn, R. (eds) Graves' Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2534-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2534-6_10
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2533-9
Online ISBN: 978-1-4939-2534-6
eBook Packages: MedicineMedicine (R0)